MedTrace Logo

Mapping And Preventing Relapse Risk in Polydrug Users

NCT07161986 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2025-09-09

No results posted yet for this study

Summary

This Interventional two-arm comparative study will evaluate whether a mindfulness-based strategy (MBS) improves outcomes for adults with substance use disorders (polydrug users) compared with treatment-as-usual (TAU). The primary question is whether MBS lowers cravings and reduces relapse risk relative to TAU; secondary aims include improvements in emotion regulation, coping, depressive/anxiety symptoms, mindfulness, and motivation to change. The design includes two arms (MBS vs TAU) with baseline and post-intervention assessments; adherence within the MBS arm will also be examined (e.g., high- vs low-adherence) to test whether greater adherence yields better primary and secondary outcomes than TAU. Primary outcomes are craving and relapse risk; secondary outcomes are emotion regulation, coping, depressive and anxiety symptoms, mindfulness, and motivation to change. Hypotheses predict that MBS will reduce cravings and depressive/anxiety symptoms and improve mindfulness and emotion regulation as compared to TAU; that psychological network structure will differ by relapse-risk level and by adherence subgroup; and that motivation to change will mediate MBS effects.

Conditions

  • Drug Addiction
  • Polysubstance Addiction

Interventions

BEHAVIORAL

Mindfullness based Sobriety (MBS)

MBS is combination of Mindfullness , Relapse prevention, motivational interviewing , acceptance and commitment therapy. It helps in dealing underlying depression and anxiety issues among Polysubstance use. it Cover most of underlying problem faced by person with addiction.

Sponsors & Collaborators

  • Institute of Psychology, Chinese Academy of Sciences

    lead OTHER

Principal Investigators

  • Li Yonghui Professor, Institute Of Psychology,Chinese Acedmy of Sciences · Institute Of Psychology,Chinese Acedmy of Sciences

  • Romana Younas PhD fellow, Mphil ClPsy · Institute of Psychology,Chinese Acedmy Of Sciences

  • Salman Shahzad Professor · Institute of Clinical Psychology,Universitry of Karachi,Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-24
Primary Completion
2025-07-15
Completion
2025-08-24

Countries

  • Pakistan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07161986 on ClinicalTrials.gov